CIK 0001815776
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 844867570
- Phone
- +1 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- 4 Open-market buy 10% owner bought 201,685 shares at $10.15 ($2,047,103)
- 4 Open-market buy 10% owner bought 50,800 shares at an average $13.14 ($667,665)
- 4 Open-market buy 10% owner bought 145,496 shares at an average $13.53 ($1,968,973)
- 4 Open-market buy 10% owner bought 180,000 shares at $17.00 ($3,060,000)
- 4 Conversion CHIEF OPERATING OFFICER acquired 8,126 shares (conversion)
- 4 Open-market buy Director bought 180,000 shares at $17.00 ($3,060,000)
- 4 Open-market buy Director bought 5,882 shares at $17.00 ($99,994)
- 4 Exercise or conversion CHIEF BUSINESS OFFICER acquired 94,789 shares (option exercise)
- 4 Exercise or conversion Director acquired 49,876 shares (option exercise)
- 4 Conversion Director acquired 8,126 shares (conversion)
- 4 Exercise or conversion PRESIDENT AND CEO acquired 374,013 shares (option exercise)
- 4 Open-market buy 10% owner bought 500,000 shares at $17.00 ($8,500,000)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 6 of 7 · 129 filings